Abbott sees profits jump 34 percent
LIBERTYVILLE TOWNSHIP - Abbott Laboratories Inc. beat Wall Street expectations Wednesday with a 34-percent jump in second-quarter profit, driven by robust sales of its blockbuster drug Humira and increased business overseas. The earnings boost came in part from surging international business, with non-U.S. pharmaceutical sales rising more than 25 percent and diagnostic sales up nearly 20 percent. Sales were led by the company's blockbuster arthritis medication Humira, which posted revenue of over $1 billion, up 48 percent from last year.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.